Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today…

Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis

March 23, 2021 07:30 AM Eastern Daylight Time NEW YORK & CHICAGO--(BUSINESS WIRE)--Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose…

EYENOVIA TO REPORT FOURTH QUARTER AND FULL YEAR 2020 RESULTS ON THURSDAY, MARCH 25

NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today…

Eyenovia to Participate in the 33rd Annual Roth Conference

NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology,…

Eyenovia Announces FDA Acceptance of the MydCombi NDA

March 02, 2021 07:30 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced…

Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase

Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase   NEW YORK--(BUSINESS WIRE)--Jan. 26, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing…

Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia

Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Topline Results Expected First Half of 2021 December 16, 2020…

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually December 29, 2020 07:00 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Eyenovia,…

Eyenovia To Report Third Quarter 2020 Results

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will…